查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1198199

報告基因檢測市場——增長、趨勢、COVID-19 的影響和預測 (2023-2028)

Reporter Gene Assay Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

報告基因檢測市場預計在預測期內（2022 年至 2027 年）以 10.1% 的複合年增長率增長。

在 COVID-19 中，由於世界各地 COVID-19 病例的增加以及對疫苗和治療藥物的需求不斷增長，預計報告基因檢測市場將擴大。. 為 COVID-19 患者開發疫苗以及人們對診斷的需求不斷增加，預計將為報告基因檢測市場創造有利可圖的機會。 此外，對 COVID-19 病毒的研究越來越多，研究其核酸結構以生產合適的候選疫苗，導致產品批准和推出激增。 例如，2021 年 8 月，Creative Diagnostics 將針對廣泛的冠狀病毒種類推出慢病毒 SARS-CoV-2 假病毒。 不同的載體可以表達不同的報告基因，例如 EGFP 或熒光素□，從而允許採用不同的方式監測病毒進入宿主細胞。 預計 COVID-19 將對市場增長產生重大影響，因為這些發布將推動與 COVID-19 相關的研究和開發。

此外，對基於細胞的分析的日益偏愛是報告基因分析市場增長的主要驅動力之一。 這是由於在生命科學研究和生物製造中越來越多地使用報告基因檢測。 報告基因檢測是研究健康細胞和患病細胞的生物化學和生理學的重要實驗工具。 因此，報告基因檢測在新發傳染病病毒的研究和藥物療法的開發中受到了極大的關注。 此外，由於慢性遺傳病和傳染病在人群中普遍存在，因此有望將細胞應用於藥物發現，報告基因檢測的需求也在增加。 根據 2022 年世界衛生組織的一份報告，癌症等慢性病是全球主要死因之一，2020 年佔死亡人數的近六分之一。 美國國家人類基因組研究所 2020 年 1 月發布的一份報告稱，估計有 6,800 多種罕見病影響著 25 至 3000 萬美國人。 因此，罕見病和遺傳病的發病率不斷增加，加上對早期診斷和有效治療過程的需求不斷增加，預計將推動市場增長。

此外，市場參與者採取的戰略舉措也有望推動市場增長。 例如，2021 年 12 月，諾華收購了英國眼科基因治療公司 Gyroscope Therapeutics 的全部股權。 此次收購幫助諾華公司將其產品組合擴展到基因治療領域。

因此，由於上述因素，市場預計在預測期內會出現增長。 然而，基於細胞的研究的高成本可能會阻礙市場增長。

報告基因檢測市場趨勢

在報告基因檢測市場，檢測試劑盒有望佔據主要市場份額

預計在預測期內，檢測試劑盒部分將產生可觀的收入。 COVID-19 的突然爆發增加了對報告基因檢測的需求，以研究未知病毒的基因表達並確保正確接種疫苗。

主要使用的有熒光蛋白相關檢測試劑盒、分泌型鹼性磷酸□（SEAP）檢測試劑盒、熒光素□檢測試劑盒、β-半乳糖甘□檢測試劑盒等。 這是因為它們越來越多地用於研究基因轉錄和翻譯水平的表達以及分析信號轉導通路。 此外，多項檢測可確保准確的信號測量和一致的結果。 此外，該測定方便、快速、靈敏，並顯示出廣泛的檢測線性模式。 此外，對建立基於細菌細胞的報告系統的 β-半乳糖甘□高通量檢測的研究興趣不斷增加，這也促進了檢測試劑盒領域的最快增長。 因此，對檢測試劑盒領域的需求激增預計將推動市場增長。

此外，市場進入者推出的檢測試劑盒也推動了該領域的發展。 例如，2021 年 6 月，QIAGEN 將推出 QIAprep&CRISPR 試劑盒，使研究人員能夠以無與倫比的速度和效率分析編輯過的遺傳物質，以確定他們的干預措施如何改變 DNA 序列的功能。並推出 CRISPR Q-Primer Solutions。

因此，由於上述因素，預計該細分市場將推動市場增長。

北美將佔據很大的市場份額，預計在預測期內也會如此。

由於用於疾病檢測的診斷和報告基因檢測產品的創新，北美地區將主導全球市場。 預計該地區將在預測期內保持其主導地位，生物技術公司和醫療設施的投資將加速基因治療的發展。

生物技術和製藥公司增加投資以建立專門研究和製造基因療法及相關基因產品的設施，這也促進了市場的增長。 例如，2020 年 12 月，Taisha Gene Therapies, Inc. 將在北卡羅來納州達勒姆開設一個約 187,000 平方英尺的現有商業規模設施，用於其基因治療管線的臨床前、臨床和商業生產。我們已經簽訂了一項租用和配置符合良好生產規範 (cGMP) 的製造設施。 此外，2021 年 12 月，輝瑞（Pfizer）宣佈在北卡羅來納州達勒姆開設一個新的最先進的臨床製造工廠。 該設施擴展了輝瑞在基因治療方面的端到端能力，並建立在公司在北卡羅來納州的現有足蹟之上。 達勒姆工廠將支持輝瑞在基因治療研發和製造方面的持續投資，過去六年投資8億美元建設三個高度可擴展的、最先進的基因治療製造設施，是建設的一部分.

此外，該地區推出的檢測試劑盒等產品也推動了市場增長。 例如，2021 年 11 月，Bio-Techne 品牌 Asuragen, Inc. 推出了一種新試劑盒，用於檢測 CFTR 基因中的致病變異，即 AmplideX PCR/CE CFTR 試劑盒，僅供研究使用。 該產品比市場上任何其他 CFTR 檢測方法更廣泛地覆蓋美國不同人群。 這些專門針對美國人口的產品也在推動市場增長。

因此，由於上述因素，預計北美地區的市場在預測期內將出現增長。

報告基因檢測市場競爭者分析

報告基因檢測市場競爭激烈，由幾家主要參與者組成。 從市場份額的角度來看，一些主要參與者目前主導著市場。 目前的市場主導者包括 Thermo Fisher Scientific、Puritan Medical Products、Trinity Biotech、Medical Wire & Equipment、Vircell、Quidel Corporation、BD、Titan Biotech Limited、Copan Diagnostics、EKF diagnostics、Hardy Diagnostics、Pretium Packaging 等。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 增加對細胞研究的資助
    • 對基於細胞的檢測的偏好不斷上升
  • 市場製約因素
    • 基於細胞的研究成本高
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分

  • 按產品分類
    • 檢測試劑盒
    • 試劑
  • 通過申請
    • 基因調控
    • 細胞信號通路
    • 其他
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Thermo Fisher Scientific
    • PerkinElmer Inc.
    • Merck KGaA
    • Bio-Rad Laboratories Inc.
    • Cell Signaling Technologies Inc.
    • Promega Corporation
    • New England Biolabs
    • Cell Biolabs Inc.
    • Eurofins DiscoverX products
    • Biotium
    • InVivoGen

第7章 市場機會與今後動向

簡介目錄
Product Code: 90460

The reporter gene assay market is projected to register a CAGR of 10.1% during the forecast period (2022-2027).

Amidst COVID-19, the reporter gene assay market is expected to grow owing to the rising cases of COVID-19 among people across the globe and the rising demand for vaccines and treatment drugs. The increase in the need for the development of vaccines for COVID-19 infected patients and the diagnosis of people is projected to create lucrative opportunities for the reporter gene assay market. Also, the increasing research on the COVID-19 virus to study the nucleic acid structure to produce suitable vaccine candidates has led to a surge in product approvals and launches. For instance, in August 2021, Creative Diagnostics launched a variety of lentiviral SARS-CoV-2 pseudoviruses from a wide range of coronavirus species. Different vectors can be used to express different reporters such as EGFP or luciferase, allowing the monitoring of viral entry into host cells by a variety of means. Such launches are expected to propel the research and development related to COVID-19 and, thus, COVID-19 is expected to have a significant impact on the growth of the market.

Moreover, the growing preference for cell-based assays is one of the major driving factors for the growth of the reporter gene assay market. This is due to the increasing usage of reported gene assays in life science research and biomanufacturing. The reporter gene assays are a crucial experimental tool to study the biochemistry and physiology of both healthy and diseased cells. Thus, the reporter gene assays gained much attention in studying emerging infectious viruses and developing drug therapies. Additionally, the increasing prevalence of chronic genetic disorders and infectious diseases among the population has led to increased demand for reporter gene assays owing to the cell-based applications in drug discovery. According to a World Health Organization report in 2022, chronic diseases such as cancer are one of the leading causes of death worldwide, accounting for nearly one in six deaths in 2020. The National Human Genome Research Institute report published in January 2020 stated that more than 6,800 rare diseases affect an estimated 25 to 30 million Americans. Therefore, the increasing incidences of rare and genetic disorders coupled with increasing demand for early diagnosis and effective treatment processes are expected to boost the growth of the market.

Additionally, the strategic initiatives undertaken by the market players are also expected to propel the growth of the market. For instance, in December 2021, Novartis acquired all share capital of the United Kingdom-based ocular gene therapy company Gyroscope therapeutics. This acquisition helped the company, Novartis, extend its portfolio into gene therapy.

Thus, owing to the abovementioned factors, the market is expected to show growth over the forecast period. However, the high cost of cell-based research may hinder the growth of the market.

Reporter Gene Assay Market Trends

The Assay Kits Segment is Expected to Hold a Major Market Share in the Reporter Gene Assay Market

The assay kits segment is expected to register significant revenue over the forecast period. The sudden outbreak of COVID-19 has increased the demand for reporter gene assays owing to their efficiency in studying the gene expression of the unknown virus to produce suitable vaccination.

The assay kits mostly used are fluorescent protein-related assay kits, secreted alkaline phosphate(SEAP) assay kits, luciferase assay kits, beta-galactosidase assay kits, and others. This is attributed to their increased usage in expression studies and signaling pathway analysis during gene transcription or translation levels. Also, the extensive usage of assays enables precise signal measurement, maintaining the consistency of the outcomes. In addition, they are convenient, fast, sensitive, and display a broadly linear pattern for detection. Moreover, the rising focus of researchers on establishing high-throughput assays of beta-galactosidase for reporter systems based on bacterial cells contributes to the fastest growth rate of the assay kit segments. This huge surge in demand for the assay kits segment is expected to propel the market's growth.

The launch of assay kits by market players is also propelling the growth of the segment. For instance, in June 2021, QIAGEN launched the QIAprep& amp; CRISPR Kit and CRISPR Q-Primer Solutions that allow researchers to analyze edited genetic material with unparalleled speed and efficiency to determine how their interventions have changed the function of the DNA sequence.

Thus, owing to the abovementioned factors, the market segment is expected to propel the growth of the market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period.

The North American region is likely to dominate the global market owing to the technological innovations in the diagnostic and reporter gene assay products used for disease testing. The region will retain its dominant position over the forecast years on account of investments by biotechnology companies and health care facilities to accelerate the development of gene therapies.

The growing investment by biotechnological and pharmaceutical companies in establishing facilities dedicated to research and manufacturing of gene therapy and related genetic products also drives the growth of the market. For instance, in December 2020, Taysha Gene Therapies, Inc. entered into a lease agreement to occupy and configure an approximately 187,000-square-foot commercial-scale current Good Manufacturing Practices (cGMP) manufacturing facility in Durham, North Carolina for preclinical, clinical, and commercial production of its gene therapy pipeline. Additionally, in December 2021, Pfizer Inc. reported the opening of a new, state-of-the-art clinical manufacturing facility in Durham, North Carolina. The facility expands Pfizer's end-to-end capabilities in gene therapy and builds on the company's existing footprint in North Carolina. The Durham facility is part of a USD 800 million investment over the past six years to build three scalable, state-of-the-art gene therapy manufacturing facilities to support Pfizer's continued investment in gene therapy research, development, and manufacturing.

In addition, the launch of products such as assay kits in the region is also propelling the growth of the market. For instance, in November 2021, Asuragen, Inc., a Bio-Techne brand, launched a new kit to detect pathogenic variants in the CFTR gene, namely the AmplideX PCR/CE CFTR kit, intended for research use only. It provides broader coverage of the diverse United States population than any other commercially available, targeted CFTR testing assay. Such products, specifically targeting the United States population, are also propelling the growth of the market.

Thus, owing to the abovementioned factors, the market in the North American region is expected to show growth over the forecast period.

Reporter Gene Assay Market Competitor Analysis

The Reporter Gene Assay Market is competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some companies currently dominating the market are Thermo Fisher Scientific, Puritan Medical Products, Trinity Biotech, Medical Wire & Equipment, Vircell, Quidel Corporation, BD, Titan Biotech Limited, Copan Diagnostics, EKF diagnostics, Hardy Diagnostics, Pretium Packaging, and others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing funding for Cell-based research
    • 4.2.2 Growing preferences of Cell- based assays
  • 4.3 Market Restraints
    • 4.3.1 High cost of the cell-based research
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Assay Kits
    • 5.1.2 Reagents
  • 5.2 By Application
    • 5.2.1 Gene Regulation
    • 5.2.2 Cell signalling pathways
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Thermo Fisher Scientific
    • 6.1.2 PerkinElmer Inc.
    • 6.1.3 Merck KGaA
    • 6.1.4 Bio-Rad Laboratories Inc.
    • 6.1.5 Cell Signaling Technologies Inc.
    • 6.1.6 Promega Corporation
    • 6.1.7 New England Biolabs
    • 6.1.8 Cell Biolabs Inc.
    • 6.1.9 Eurofins DiscoverX products
    • 6.1.10 Biotium
    • 6.1.11 InVivoGen

7 MARKET OPPORTUNITIES AND FUTURE TRENDS